Skip to main content
Caplight Logo









Ikarovec

Ikarovec

Private
NorwichHealthcare & Life Scienceshttps://ikarovec.com/

Last Round

Series A

Oct 22, 2025

Total Funding Raised

$10.78M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ikarovec is a biotechnology company that develops novel, multi-cistronic gene therapies for ophthalmic diseases such as age-related macular degeneration and diabetic macular edema.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyophthalmic diseaseeye gene therapybiotechnologyophthalmology biotechintravitreal deliveryretinal gene therapyretinal diseasedrug discoveryclinical-stage biotechbiologicscapsid deliverybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ikarovec Comparables

Compare Ikarovec with similar companies based on industry and business-model similarity.

Ikarovec comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Atsena Therapeutics
81%
Beacon Therapeutics
79%
Olive Bio Therapeutics
78%

Ikarovec Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 22, 2025
SeedOct 23, 2024
GrantJun 15, 2020
SeedFeb 5, 2020

Ikarovec Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 72% MoM, from 1.1K to 1.9K.

  • Jan 6, 2026

    Developing IKAR-003 with VectorBuilder Inc. for disease progression prevention.

Ikarovec Filings

Explore SEC and related filing metadata, where available.

Ikarovec filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ikarovec's valuation, stock price, and market status.

Is Ikarovec a public or private company?

Ikarovec is a private company.

What is the current stock price of Ikarovec?

Ikarovec is a private company with no public stock price. No recent secondary market data is available.

How much is Ikarovec worth (valuation)?

Valuation information for Ikarovec is not publicly available.

Can I buy Ikarovec stock?

Ikarovec shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ikarovec's last funding round?

Ikarovec's most recent funding round was Series A on October 22, 2025.

Who are the main investors in Ikarovec?

Key investors in Ikarovec include UK Innovation & Science Seed Fund, LifeArc Ventures, LifeArc, Parkwalk Advisors.

Will Ikarovec IPO soon?

No public IPO plans have been announced for Ikarovec.

How can I track Ikarovec secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ikarovec's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNorwich
Employee Range10
Year Founded2020
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?